Business Context and Reporting Period
Amphastar Pharmaceuticals, Inc. (AMPH) filed a Form 8-K on July 5, 2022, reporting the entry into a material definitive agreement. The Company is a Delaware corporation with principal executive offices in Rancho Cucamonga, California.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The financial impact is limited to the terms of a new contract research agreement.
- Total Agreement Cost: Not to exceed approximately $2.2 million.
- Initial Payment: Approximately $0.2 million paid on the Effective Date (July 5, 2022).
- Currency: Payments are made in Chinese yuan, adjusted based on actual exchange rates.
- Additional Costs: Charged on a cost-plus basis for any work outside the original Scope of Work, subject to Company approval.
Material Changes
The primary material change is the execution of a three-year contract research agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. ("Hanxin"). Under this agreement, Hanxin will develop Recombinant Human Insulin Research Cell Banks (RCBs) for the Company. The Company will receive a fully paid, exclusive, perpetual, transferable, and sub-licensable worldwide license to the RCBs. All title to the RCBs and related proprietary information will belong to the Company.
Outlook, Risks, and Related Party Transaction
Related Party Transaction: The agreement is a related party transaction. Dr. Jack Zhang (CEO, President, Director), Dr. Mary Luo (Chairman, COO, Director), and certain members of their families beneficially own a majority of the equity interest in Hanxin. The transaction was evaluated and approved by the independent and disinterested members of the Audit Committee.
Risks and Contingencies: The filing notes that additional costs may arise if the Company requests changes to the Scope of Work. The agreement is subject to customary representations, warranties, and covenants. The full text of the agreement will be filed as an exhibit to the Company's Form 10-Q for the quarter ending September 30, 2022.
Investor Verification Checklist
- Verify the final total cost of the agreement against the $2.2 million cap in future financial reports.
- Confirm the progress of the RCB development and the timeline for creating Master Cell Banks.
- Review the full Agreement text in the upcoming Form 10-Q for detailed Scope of Work and termination clauses.
- Monitor for any additional cost-plus charges resulting from changes to the Scope of Work.